Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BOSTON PROPERTIES, INC.

(BXP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Boston Properties : Builds on Its Growing Life Sciences Portfolio, Acquires Lab Properties in Waltham, Massachusetts

06/04/2021 | 07:01am EDT

Boston Properties, Inc. (NYSE: BXP), the largest publicly traded developer, owner, and manager of Class A office properties in the United States, announced today that it has acquired 153 & 211 Second Avenue, two lab properties comprising 153,000 square-feet in Waltham, Massachusetts, a highly desirable location for leading and emerging companies in the life sciences and biotechnology sector. The Company acquired the two lab buildings from an affiliate of Montana Avenue Capital Partners, LLC for a gross purchase price of $100 million in cash.

153 & 211 Second Avenue are 100% leased to a leading pharmaceutical company and are adjacent to BXP’s 200 West Street building, a 272,000 square feet property, a portion of which was recently converted to lab space, that is 100% leased to Translate Bio. The acquisition builds on BXP’s 4.9 million square feet of lab and Class A office properties in the Waltham/Lexington region of Massachusetts.

“Waltham continues to be a dominant urban edge location for life sciences organizations that want to attract and retain highly-educated talent,” said Bryan Koop, Executive Vice President, Boston Region, BXP. “The 153 & 211 Second Avenue campus provides both location and amenities that offer long-term value for current and prospective clients and is another example of BXP’s ability to meet the growing demand of companies in the biotechnology sector.”

“The adjacency to our 200 West Street lab space and our medical space at 195 West Street creates a significant opportunity for another BXP life sciences cluster in the Waltham market. This complements our existing life sciences presence in the Waltham market and allows us to meet ongoing demand from this important sector,” stated David Provost, Senior Vice President of Development, Co-Head of BXP Life Sciences, Boston Properties.

About BXP Life Sciences

BXP Life Sciences consists of an existing portfolio of more than three million square feet focused on the specific needs of the life sciences industry, primarily in the leading innovation markets of Boston, Cambridge, and Waltham/Lexington, Massachusetts and San Francisco and Los Angeles, California. In addition, BXP has approximately six million square feet of life sciences-focused development opportunities, including approximately one million square feet of current lab developments and redevelopments in process that are expected to deliver in the next 24-36 months.

About Boston Properties

Boston Properties (NYSE: BXP) is the largest publicly-held developer and owner of Class A office properties in the United States, concentrated in five markets - Boston, Los Angeles, New York, San Francisco and Washington, DC. The Company is a fully integrated real estate company, organized as a real estate investment trust (REIT), that develops, manages, operates, acquires and owns a diverse portfolio of primarily Class A office space. Including properties owned by joint ventures, the Company’s portfolio totals 51.6 million square feet and 196 properties, including nine properties under construction/redevelopment. For more information about Boston Properties, please visit our website at www.bxp.com or follow us on LinkedIn or Instagram.

This press release contains forward-looking statements within the meaning of the Federal securities laws. You can identify these statements by our use of the words “will,” “expects,” “intends” and similar expressions that do not relate to historical matters. You should exercise caution in interpreting and relying on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Boston Properties’ control and could materially affect actual results, performance or achievements. These factors include, without limitation, Boston Properties’ ability to complete the developments and redevelopments referenced above on time or at all and other risks and uncertainties detailed from time to time in Boston Properties’ filings with the SEC. Boston Properties does not undertake a duty to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.


ę Business Wire 2021
All news about BOSTON PROPERTIES, INC.
08:38aBOSTON PROPERTIES : Goldman Sachs Adjusts Boston Properties' Price Target to $11..
MT
08:37aBOSTON PROPERTIES : Argus Adjusts Price Target on Boston Properties to $132 From..
MT
07/29BOSTON PROPERTIES : Marks Groundbreaking of 180 CityPoint
BU
07/29Boston Properties Marks Groundbreaking of 180 CityPoint
CI
07/29BOSTON PROPERTIES : UBS Adjusts Boston Properties' Price Target to $117 From $11..
MT
07/27BOSTON PROPERTIES : Climbing in Late Trade After Q2 Results Top Wall Street Fore..
MT
07/27BOSTON PROPERTIES INC : Results of Operations and Financial Condition, Financial..
AQ
07/27BOSTON PROPERTIES : Q2 Earnings Snapshot
AQ
07/27BOSTON PROPERTIES : Expands Its Life Sciences Growth Opportunity; Agrees to Acqu..
BU
07/27BOSTON PROPERTIES : to Extend Its New York Presence Into the Midtown South Subma..
BU
More news
Financials (USD)
Sales 2021 2 844 M - -
Net income 2021 401 M - -
Net Debt 2021 12 200 M - -
P/E ratio 2021 46,5x
Yield 2021 3,37%
Capitalization 18 165 M 18 165 M -
EV / Sales 2021 10,7x
EV / Sales 2022 10,3x
Nbr of Employees 750
Free-Float 99,7%
Chart BOSTON PROPERTIES, INC.
Duration : Period :
Boston Properties, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BOSTON PROPERTIES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 23
Last Close Price 116,34 $
Average target price 120,50 $
Spread / Average Target 3,58%
EPS Revisions
Managers and Directors
Owen D. Thomas Chief Executive Officer & Director
Douglas T. Linde President & Director
Michael E. LaBelle Chief Financial Officer, Treasurer & Executive VP
Joel Irwin Klein Independent Non-Executive Chairman
James J. Whalen Chief Information Officer & Senior Vice President
Sector and Competitors